Ella And Plan B: Complementary, Competitive Or Confusion?
Executive Summary
HRA Pharma's emergency contraceptive Ella (ulipristal acetate) is effective up to five days after unprotected intercourse or contraceptive failure, overlapping with the three-day efficacy period of Teva's Plan B (levonorgestrel). But whether the result will be harmonious market niche carving or confusion remains to be seen
You may also be interested in...
Post-Marketing Study Of Emergency Contraceptive Ella Would Be Challenging
FDA and its Reproductive Health Drugs Advisory Committee could not agree on the shape that post-marketing surveillance of HRA Pharma's emergency contraceptive Ella (ulipristal acetate) should take
Emergency Contraceptive's Length Of Efficacy Likely Focus Of FDA Panel
The Reproductive Health Drugs Advisory Committee will consider the the five-day claim sought by HRA Pharma's Ella (ulipristal acetate) which would give it a two-day advantage over Teva's Plan B (levonorgestrel) in preventing pregnancy after unprotected intercourse.
Plan B Lightning May Strike Again: Compliance May Not End Political Storm
Perpetual political lightning rod - and emergency contraceptive - Plan B will have more chances to draw strikes to FDA as the agency chooses to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the-counter setting